ロード中...
Serum levels of reactive oxygen metabolites at 12 weeks during tocilizumab therapy are predictive of 52 weeks-disease activity score-remission in patients with rheumatoid arthritis
BACKGROUND: To verify whether serum levels of reactive oxygen metabolites (ROM) are predictive of future clinical remission in patients with rheumatoid arthritis (RA) receiving tocilizumab (TCZ) therapy. METHODS: A total of 46 patients with RA receiving TCZ therapy were enrolled in this study. Patie...
保存先:
| 出版年: | BMC Rheumatol |
|---|---|
| 主要な著者: | , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2019
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6912997/ https://ncbi.nlm.nih.gov/pubmed/31891116 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s41927-019-0096-1 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|